Can I get colistin prescribed by my GP in the EU?

No. Colistin is restricted to hospital prescription and administration in all EU member states. Your GP cannot prescribe it for outpatient use. Only hospital specialists—typically infectious disease consultants or intensivists—initiate colistin therapy in inpatient settings.

Is colistin illegal to possess in the EU?

Colistin is not illegal to possess if it is prescribed by a licensed physician and obtained from an authorised pharmacy or hospital. However, obtaining it without a valid prescription, or importing it from outside the EU, is illegal.

Why is colistin use so restricted if it's approved?

Colistin is approved because it is essential for treating infections resistant to all other antibiotics. Restrictions exist because it causes serious kidney damage in 30–60% of patients and because overuse would generate resistance to this drug of last resort, putting future patients at risk.

What should I do if I'm prescribed colistin?

Accept blood tests to monitor kidney function before and during treatment. Ask your doctor why colistin was chosen and what resistance was identified. Ensure you understand the signs of kidney injury (reduced urine output, swelling, fatigue) and report any concerns immediately.

Will colistin eventually be phased out in the EU?

Not necessarily. While European researchers are developing less toxic alternatives, colistin will likely remain in use for the foreseeable future as a true last-resort agent. The EU's goal is to preserve it strategically while developing better options.

Colistin Legal Status in the EU: Approved & Restricted

Colistin is a legally approved antibiotic in the European Union, authorised by the European Medicines Agency (EMA) for use as a last-resort treatment against multidrug-resistant bacterial infections. Unlike some antibiotics with broad prescription flexibility, colistin's EU approval comes with strict restrictions: it is reserved for serious infections where conventional antibiotics have failed, and its use is closely monitored due to significant risk of kidney damage. It cannot be purchased over-the-counter and requires hospital-level prescription and clinical oversight.

Colistin's Regulatory Status in the EU

Colistin (also known as polymyxin E) holds full marketing authorisation in the European Union under the EMA's centralised approval procedure. This means it has passed rigorous safety and efficacy standards and is legally available for prescription across all EU member states. However, approval does not equal unrestricted access—colistin operates under a carefully controlled framework designed to preserve its effectiveness as infections become increasingly resistant to standard treatments.

EMA Authorisation & Approved Products

The EMA authorises specific branded formulations of colistin rather than colistin as a generic substance. Products like Colimycin (intravenous colistin methanesulfonate) hold full marketing authorisation and can be lawfully prescribed in hospital settings across EU countries. The EMA's approval reflects the agency's acceptance that despite colistin's toxicity profile, its clinical benefit in treating pan-resistant infections outweighs the risks when used in appropriate clinical contexts.

Approval was not straightforward historically. Colistin was first synthesised in 1949 and approved globally in the late 1950s, but fell out of favour for decades due to documented nephrotoxicity (kidney damage). Its reintroduction in the 2000s came as a response to the global multidrug-resistance crisis—particularly the emergence of carbapenem-resistant Enterobacteriaceae (CRE) and Pseudomonas aeruginosa strains. The EMA re-evaluated colistin's risk-benefit profile in this context and concluded that for patients with no other therapeutic options, the benefit justified controlled use.

Restrictions & Clinical Controls

Hospital-Only Prescription

In practice, colistin is almost exclusively administered in hospital or intensive care settings. It is not available for outpatient oral use and cannot be dispensed by community pharmacies for home administration. This restriction is not a legal prohibition per se, but reflects the clinical reality that colistin requires:

Intravenous administration (for systemic infection)
Intensive kidney function monitoring (baseline and during therapy)
Specialist medical oversight
Access to emergency facilities if adverse events occur

Antimicrobial Stewardship Requirements

EU member states implement antimicrobial stewardship policies that further restrict colistin use. These are not part of the EMA's marketing authorisation itself, but are recommendations and regulations set by national health authorities and hospital infection control committees. Colistin is typically reserved for:

Infections caused by carbapenem-resistant organisms
Conditions where alternative treatments have failed or are contraindicated
Situations where culture-guided sensitivity testing confirms susceptibility to colistin

Hospitals maintain colistin use protocols and may require infectious disease consultation before initiation. Some European hospitals place colistin on restricted formularies, meaning standard prescribers must request approval from a pharmacy or infection specialist.

Regulatory History: From Abandonment to Reapproval

Colistin's legal journey in the EU mirrors global trends but was shaped by specific European regulatory pressures. In the 1970s–1990s, as less toxic alternatives became available, colistin largely disappeared from European pharmacies and hospital formularies. Its nephrotoxicity—documented in roughly 30–60% of intravenous recipients—made it a poor first-line choice when safer options existed.

The turning point came in the early 2000s. As resistance to fluoroquinolones, cephalosporins, and carbapenems accelerated, European infectious disease specialists began publishing case series and observational data showing colistin's effectiveness against otherwise untreatable infections. The EMA responded by ensuring that authorised colistin products remained available and by maintaining a regulatory pathway for their supply.

A pivotal regulatory moment occurred in 2015 when researchers discovered the mcr-1 resistance gene—a transferable genetic element that could enable even colistin-resistant bacteria. This finding prompted the European Commission and EMA to issue guidance emphasising the strategic importance of preserving colistin as a truly last-resort agent. Several EU member states subsequently strengthened antimicrobial stewardship rules to limit colistin use further, reinforcing that it should only be deployed when all other options are exhausted.

Clinical Trial Activity & Evidence in Europe

There are currently 119 clinical trials registered globally involving colistin, with a significant proportion conducted in European hospitals and research centres. Notable European studies have investigated:

Combination therapy approaches (e.g., colistin plus rifampicin or high-dose fluoroquinolones) to improve outcomes in resistant Pseudomonas infections
Dosing optimisation to reduce nephrotoxicity while maintaining efficacy
Inhaled colistin formulations for respiratory tract infections (particularly in cystic fibrosis patients, where inhalation is off-label but established practice)

These trials operate within the EU Clinical Trials Regulation (EU) No 536/2014, ensuring that any colistin research meets rigorous informed consent and safety monitoring standards.

Enforcement & Compliance Across Member States

While the EMA authorises colistin centrally, enforcement of prescribing restrictions and regulatory oversight occurs at the national level. Each EU member state has its own medicines regulatory authority (e.g., the MHRA in the UK, the BfArM in Germany, the ANSM in France) that ensures compliance with:

Prescription-only status
Appropriate indications (resistance confirmed via culture)
Monitoring of adverse events through pharmacovigilance systems
Reporting of colistin-resistant infections to epidemiological surveillance networks

Breaches—such as prescribing colistin for non-resistant infections or outside hospital settings—are investigated as potential violations of national medicines laws and can result in professional sanctions for prescribers and restrictions on supply to institutions.

What Consumers Should Know

You Cannot Self-Obtain Colistin

Colistin is not available without prescription in any EU member state, and it cannot be ordered from online pharmacies legally. Attempting to source it outside medical oversight is both legally prohibited and medically dangerous.

Colistin is Only for Last-Resort Use

If a doctor prescribes colistin, it signals that your infection is extremely serious and resistant to standard treatments. This is not a sign of medical alarm, but an indicator that you are receiving the most appropriate available therapy.

Kidney Monitoring is Non-Negotiable

Patients receiving colistin must consent to regular blood tests to monitor kidney function (serum creatinine, estimated glomerular filtration rate). This is a legal and clinical requirement, not optional.

The Resistance Threat is Real

The 2015 discovery of the mcr-1 resistance gene has made colistin's preservation a matter of public health policy across the EU. Appropriate use—only when truly necessary—helps ensure it remains effective for future patients who may desperately need it.

Next-Generation Alternatives Under Investigation

Recognising colistin's limitations, pharmaceutical researchers in Europe and globally are developing next-generation polymyxin antibiotics designed to retain efficacy against resistant gram-negative bacteria while reducing nephrotoxicity. Some of these candidates are progressing through EMA-regulated clinical trials, though none have yet achieved marketing authorisation. This ongoing research reflects the EU's commitment to eventually replacing colistin with safer alternatives.

Related Compounds & Further Context

Colistin is one of several antibiotics in the polymyxin family. Similar compounds with different regulatory profiles include polymyxin B, which has similar restrictions, and emerging candidates like murepavadin (still under investigation in clinical trials in Europe). Understanding colistin's role also requires familiarity with the carbapenem resistance crisis that drove its reintroduction.

Key Takeaways

Colistin is legally approved in the EU via EMA marketing authorisation, but access is tightly controlled
Hospital-only use is the practical standard; community dispensing is not permitted
Antimicrobial stewardship rules further restrict prescribing to documented resistance and last-resort scenarios
Kidney monitoring is a mandatory part of any colistin course
National authorities enforce compliance within EU member states
Research continues to develop less toxic alternatives as part of EU public health strategy

Colistin Legal Status in the EU: EMA Approval, Restrictions & What You Need to Know